Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 · kind B2 · utility
36Cited by
33References
52Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 17, 2001 |
| Grant date | Dec 31, 2002 |
| Priority date | — |
| Expiry date | Aug 17, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention provides compounds of Formula I: These compounds may be in the form of pharmaceutical salts or compositions, and racemic mixtures or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.